Xintela to develop stem cell therapy for difficult-to-heal wounds
Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with […]
Targinta recruits Per Norlén as CEO
Lund, Sweden, May 4, 2021 – Xintela announces today that Per Norlén has been recruited as CEO of Xintela’s wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela’s Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in […]
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
Lund, Sweden, 6 April 2021 – Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate the potential of the company’s stem cell product XSTEM® in the treatment of ARDS, a life-threatening lung complication that can affect severely ill COVID-19 […]
Xintela gets tissue establishment license
Lund, Sweden, 19 March 2021 – Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products. In order to conduct activities that use human tissues and cells for the manufacture of medicinal products, a tissue establishment license […]
Xintela gets patent grant in Europe for XSTEM stem cell product
Lund, Sweden, 17 March 2021 – Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company’s stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells. Xintela previously announced (October 29, 2020) the preliminary approval of its European patent application from the EPO for the XSTEM stem […]
Xintela publishes results from glioblastoma antibody study
Lund, Sweden, March 12, 2021 – Xintela announces that the results of the company’s preclinical glioblastoma study with function-blocking antibodies have today been published in the renowned international scientific journal Cancers. The publication shows, among other things, that antibodies directed to the company’s target molecule integrin 101 significantly reduce the growth of the aggressive and […]
Year-end report 1 Jan – 31 Dec 2020
Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Twelve months (1 Jan 2020-31 Dec 2020) Net sales amounted to TSEK 0 (38). Loss before tax totalled TSEK 50,257 (loss: 43,530). Loss per share* was SEK 0.68 (loss: 1.10). At 31 December 2020, the equity/assets ratio** […]
Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors
Lund, Sweden, January 7, 2021 – Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintela’s patent application 15/550,837 in the USA protects the use of the target molecule integrin […]
Xintela submits manufacturing license application
Lund, Sweden, 21 December 2020 – Xintela announces today that the company has submitted its application to the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies. Xintela has developed and patented the stem cell product platform XSTEM® and built its […]
Xintela recruits Jeffrey Abbey to Targinta
Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of […]
